REVERSE-VACCINOLOGY APPROACH TO DEVELOP VACCINE AGAINST RED SEA BREAM IRIDOVIRUS (RSIV)
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
KARNATAKA VETERINARY, ANIMAL AND FISHERIES SCIENCES UNIVERSITY, BIDAR
Abstract
Reverse vaccinology (RV) is a modern technique that accelerates the discovery of
potential vaccine candidates suitable in vaccine development. Red sea bream iridovirus
(RSIV) is the etiological agent responsible for Red sea bream iridovirus disease (RSIVD)
in fish leading to huge economic losses to the aquaculture industry. The present study was
aimed to screen, isolate, characterize RSIV genome and develop a vaccine candidate using
the RV approach to control the RSIV infection. In this study RSIV was isolated from a
moribund Asian sea bass cultured in estuarine cages. The PCR amplification and
sequencing results of the DNA polymerase gene showed similarity with the sequences of RSIV
strains from other countries. Experimental infection studies revealed 100% mortality in the
RSIV challenged Asian sea bass on 6th day post infection (dpi). Histopathogical observations in the
spleen, kidney and liver tissues were similar to that of typical RSIV infection. Replication
efficiency test in the fish cell lines revealed that the RSIV could infect eleven cell lines with viral
titers ranging from 102.6 to 106.3 TCID50/ml. The Illumina Hiseq sequencing of RSIV revealed that
the complete genome size of RSIV is 111,557 bp with GC content of 53%. The phylogenetic
analysis of the 26 core genes including Major capsid protein indicated that the virus belong
to the genus Megalocytivirus of the RSIV-Genotype II. The genome encoded 114 ORFs of
which 38 ORFs were predicted as functional proteins while the rest were hypothetical
proteins. Of the 114, two proteins (MCP and ORF036) were identified as potential vaccine
candidates using the RV strategy. The vaccine targets were cloned and expressed in
Escherichia coli BL21 (DE3) cells. Asian sea bass vaccinated (injection method) with
purified recombinant proteins, MCP and ORF036 emulsified with ISA763 adjuvant
showed protection against RSIV infection with relative percentage survival of 76.7% and
63%, respectively.